Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 19NIH 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 2Gastrointestinal 2Dermatologic 2Breast 2Gynecologic 1

Conditions

Breast Neoplasms 71Lymphoma, Large B-Cell, Diffuse 51Neoplasms 41Lymphoma, Non-Hodgkin 41Multiple Myeloma 40Lymphoma 37Recurrence 33Lymphoma, Follicular 30Carcinoma, Non-Small-Cell Lung 30Leukemia, Lymphocytic, Chronic, B-Cell 29Lymphoma, B-Cell 26Triple Negative Breast Neoplasms 23Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Mantle-Cell 17Ovarian Neoplasms 15Leukemia 15Pancreatic Neoplasms 14Neoplasm Metastasis 14Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Melanoma 11Colorectal Neoplasms 11Lymphoma, B-Cell, Marginal Zone 10Prostatic Neoplasms 9Lymphoma, T-Cell, Peripheral 8Liposarcoma, Myxoid 8Head and Neck Neoplasms 8Carcinoma, Renal Cell 8Sarcoma 7

Interventions

Pemetrexed 3mifamurtide 2lenvatinib 2dostarlimab 2belinostat 2Ifosfamide 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gemcitabine 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2vactosertib 1surufatinib 1sintilimab 1robatumumab 1ridaforolimus 1reolysin 1pembrolizumab 1pazopanib 1omburtamab I-131 1niraparib 1isophosphamide mustard 1fludarabine 1endostar protein 1dinutuximab 1copanlisib 1cc-486 1cabozantinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Osteosarcoma × Cyclophosphamide × Clear all
NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Valo Therapeutics Oy

Phase 1 Recruiting
15 enrolled
BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT04282044 2024-02-08

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

BioEclipse Therapeutics

Phase 1 Recruiting
60 enrolled
BreastDermatologicGastrointestinalGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Osteosarcoma, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡